References
- Helmick CG, Lee-Han H, Hirsch SC, et al. Prevalence of psoriasis among adults in the US: 2003–2006 and 2009–2010. National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47(1):37–45.
- Saurat JH, Stingl G, Dubertret L, Papp K, Langley R, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2007;158(3):558–566.
- Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venerol. 2015;95(2):133–139.
- Benzocaine. Physicians’ desk reference. 60th ed. Stamford (CT): Thompson Health Care; 2006.
- Sbidian E, Chaimani A, Garcia‐Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database Syst Rev. 2017;12:CD011535.
- Puig L. PASI 90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
- Zachariae H. Methotrexate side‐effects. Br J Dermatol. 1990;122(s36):127–133.
- International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-9 CM). 2011. Available from http://www.cdc.gov/nchs/icd/icd10cm.htm.
- National Ambulatory Medical Care Survey [Internet]. 2016. Available from https://www.cdc.gov/nchs/ahcd/datasets_documentation_related.htm
- Questionnaires, Datasets, and Related Documentation CDC. [cited 27 Dec 2019] http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm
- Roenigk HH, Jr., Bergfeld WF, Jacques RS, Owens FJ, et al. Hepatotoxicity of methotrexate the treatment of psoriasis. Arch Dermatol. 1971;103(3):250–261.
- Correia B, Torres T. Obesity: a key component of psoriasis. Acta Biomed. 2015;86(2):121–129.
- Fleischer AB Jr. Characterization of obesity rates for dermatologic ambulatory office visits to United States physicians. J Dermatol Treat. 2017;28(2):181–185.
- Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. The Lancet. 2012;380(9843):738–746.
- Rønholt K, Iversen L. Old and new biological therapies for psoriasis. IJMS. 2017;18(11):2297.
- Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46–54.